New Zealand markets closed

Esperion Therapeutics, Inc. (ESPR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.5900-0.0800 (-4.79%)
At close: 04:00PM EDT
1.6300 +0.04 (+2.52%)
After hours: 07:55PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 142.04M
Enterprise value 236.13M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.37
Price/book (mrq)74.89
Enterprise value/revenue 3.13
Enterprise value/EBITDA -1.34

Trading information

Stock price history

Beta (5Y monthly) 0.25
52-week change 3-69.71%
S&P500 52-week change 3-10.33%
52-week high 38.8700
52-week low 31.2600
50-day moving average 34.7840
200-day moving average 36.3801

Share statistics

Avg vol (3-month) 33.83M
Avg vol (10-day) 34.72M
Shares outstanding 588.78M
Implied shares outstanding 6N/A
Float 866.34M
% held by insiders 10.77%
% held by institutions 185.73%
Shares short (14 Mar 2023) 418.67M
Short ratio (14 Mar 2023) 45.01
Short % of float (14 Mar 2023) 429.25%
Short % of shares outstanding (14 Mar 2023) 424.39%
Shares short (prior month 14 Feb 2023) 416.47M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Dec 2022


Profit margin 0.00%
Operating margin (ttm)-237.83%

Management effectiveness

Return on assets (ttm)-35.64%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)75.47M
Revenue per share (ttm)1.14
Quarterly revenue growth (yoy)22.20%
Gross profit (ttm)-70.42M
Net income avi to common (ttm)-233.66M
Diluted EPS (ttm)-3.1600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)166.86M
Total cash per share (mrq)2.18
Total debt (mrq)504.55M
Total debt/equity (mrq)N/A
Current ratio (mrq)2.67
Book value per share (mrq)-4.34

Cash flow statement

Operating cash flow (ttm)-174.83M
Levered free cash flow (ttm)-135.56M